FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1588538733> ?p ?o ?g. }

• W1588538733 endingPage "1273" @default.
• W1588538733 startingPage "1273" @default.
• W1588538733 abstract "5421 A phase III study of anthracycline-naive women with metastatic breast cancer by the National Cancer Institute of Canada Clinical Trials Group (MA.19) revealed that treatment of patients with doxorubicin in combination with N,N-Diethyl-2-[4-(Penylmethyl)Phenoxy]Ethanamine (tesmilifene) was superior to doxorubicin alone in terms of overall survival (P=0.021), with no difference seen in response rate or progression free survival (J. Clin. Oncol. 22: 269-276, 2004). One possible explanation for this observation may be that tesmilifene specifically increases the cytotoxicity of chemotherapy drugs only in rare drug-resistant cells, thus inhibiting the development of drug-resistant tumors over time. To assess this hypothesis, we examined in a clonogenic assay the effect of tesmilifene (at concentrations ranging from 0.1 to 6 μM) on the ability of doxorubicin or paclitaxel to kill wildtype MCF-7 breast tumor cells and isogenic MCF-7 cells resistant to doxorubicin or paclitaxel (MCF-7 DOX and MCF-7 TAX cells, respectively). Consistent with the above hypothesis, tesmilifene decreased the concentration at which 50% of MCF-7 TAX cells were killed by paclitaxel (the IC 50 ) in a dose-dependent manner by as much as 4-fold (at 6 μM tesmilifene), while having little effect or increasing the IC 50 for paclitaxel in wildtype MCF-7 cells, even at the highest concentration of tesmilifene. Cross resistance to doxorubicin in MCF-7 TAX cells was also reduced in a dose-dependent manner by as much as 4-fold by tesmilifene, while only slightly increasing the IC 50 for doxorubicin in wildtype MCF-7 cells at the highest concentration of tesmilifene. The IC 50 for doxorubicin was decreased by as much as 2.5-fold upon the addition of tesmilifene to MCF-7 DOX cells (also in a dose-dependent manner), with little change in the IC 50 for doxorubicin in wildtype cells. Since our MCF-7 TAX cell line overexpresses P-glycoprotein (P-gp), while our MCF-7 DOX cell line does not, it would appear that the effect of DPPE on the cytotoxicity of chemotherapy drugs in drug-resistant cells is not P-gp-specific, although this may be enhanced in P-gp-expressing cell lines. While accumulation of paclitaxel or doxorubicin was reduced in MCF-7 TAX and MCF-7 DOX cells, respectively, tesmilifene (at a 3 μM concentration) had no effect on the uptake of paclitaxel or doxorubicin into MCF-7, MCF-7 TAX , and MCF-7 DOX cells. Taken together, our data demonstrate that tesmilifene augments the cytotoxicity of paclitaxel and doxorubicin but only in drug-resistant cells through a mechanism unrelated to drug accumulation defects inherent in these cell lines." @default.
• W1588538733 created "2016-06-24" @default.
• W1588538733 creator A5015401588 @default.
• W1588538733 creator A5052673141 @default.
• W1588538733 creator A5088317387 @default.
• W1588538733 date "2006-04-15" @default.
• W1588538733 modified "2023-09-24" @default.
• W1588538733 title "Preferential potentiation of paclitaxel and doxorubicin cytotoxicity in drug-resistant breast tumor cells by tesmilifene." @default.
• W1588538733 hasPublicationYear "2006" @default.
• W1588538733 type Work @default.
• W1588538733 sameAs 1588538733 @default.
• W1588538733 citedByCount "0" @default.
• W1588538733 crossrefType "journal-article" @default.
• W1588538733 hasAuthorship W1588538733A5015401588 @default.
• W1588538733 hasAuthorship W1588538733A5052673141 @default.
• W1588538733 hasAuthorship W1588538733A5088317387 @default.
• W1588538733 hasConcept C109316439 @default.
• W1588538733 hasConcept C117262875 @default.
• W1588538733 hasConcept C121608353 @default.
• W1588538733 hasConcept C126322002 @default.
• W1588538733 hasConcept C143998085 @default.
• W1588538733 hasConcept C185592680 @default.
• W1588538733 hasConcept C202751555 @default.
• W1588538733 hasConcept C2776694085 @default.
• W1588538733 hasConcept C2776802502 @default.
• W1588538733 hasConcept C2777292972 @default.
• W1588538733 hasConcept C2781303535 @default.
• W1588538733 hasConcept C502942594 @default.
• W1588538733 hasConcept C530470458 @default.
• W1588538733 hasConcept C55493867 @default.
• W1588538733 hasConcept C71924100 @default.
• W1588538733 hasConcept C98274493 @default.
• W1588538733 hasConceptScore W1588538733C109316439 @default.
• W1588538733 hasConceptScore W1588538733C117262875 @default.
• W1588538733 hasConceptScore W1588538733C121608353 @default.
• W1588538733 hasConceptScore W1588538733C126322002 @default.
• W1588538733 hasConceptScore W1588538733C143998085 @default.
• W1588538733 hasConceptScore W1588538733C185592680 @default.
• W1588538733 hasConceptScore W1588538733C202751555 @default.
• W1588538733 hasConceptScore W1588538733C2776694085 @default.
• W1588538733 hasConceptScore W1588538733C2776802502 @default.
• W1588538733 hasConceptScore W1588538733C2777292972 @default.
• W1588538733 hasConceptScore W1588538733C2781303535 @default.
• W1588538733 hasConceptScore W1588538733C502942594 @default.
• W1588538733 hasConceptScore W1588538733C530470458 @default.
• W1588538733 hasConceptScore W1588538733C55493867 @default.
• W1588538733 hasConceptScore W1588538733C71924100 @default.
• W1588538733 hasConceptScore W1588538733C98274493 @default.
• W1588538733 hasLocation W15885387331 @default.
• W1588538733 hasOpenAccess W1588538733 @default.
• W1588538733 hasPrimaryLocation W15885387331 @default.
• W1588538733 hasRelatedWork W1002018535 @default.
• W1588538733 hasRelatedWork W1580122556 @default.
• W1588538733 hasRelatedWork W1986087165 @default.
• W1588538733 hasRelatedWork W2028374439 @default.
• W1588538733 hasRelatedWork W2053551315 @default.
• W1588538733 hasRelatedWork W2060131504 @default.
• W1588538733 hasRelatedWork W2063069570 @default.
• W1588538733 hasRelatedWork W2082976830 @default.
• W1588538733 hasRelatedWork W2351460826 @default.
• W1588538733 hasRelatedWork W2355455186 @default.
• W1588538733 hasRelatedWork W2367465317 @default.
• W1588538733 hasRelatedWork W2378714657 @default.
• W1588538733 hasRelatedWork W2378945187 @default.
• W1588538733 hasRelatedWork W2394266840 @default.
• W1588538733 hasRelatedWork W2794014465 @default.
• W1588538733 hasRelatedWork W2890844926 @default.
• W1588538733 hasRelatedWork W2993421633 @default.
• W1588538733 hasRelatedWork W3028735522 @default.
• W1588538733 hasRelatedWork W3046758594 @default.
• W1588538733 hasRelatedWork W3184310518 @default.
• W1588538733 hasVolume "66" @default.
• W1588538733 isParatext "false" @default.
• W1588538733 isRetracted "false" @default.
• W1588538733 magId "1588538733" @default.
• W1588538733 workType "article" @default.